Venus Concept Inc. (NASDAQ:VERO) Outshines in Capital Efficiency Among Peers

Venus Concept Inc. (NASDAQ:VERO) is a global medical technology company that specializes in developing and commercializing minimally invasive and non-invasive medical aesthetic and hair restoration technologies. The company operates in a competitive market alongside peers like NeuroBo Pharmaceuticals, ThermoGenesis Holdings, Plus Therapeutics, Exicure, and Acutus Medical. These companies are involved in various aspects of medical technology and pharmaceuticals, each with unique financial metrics.

Venus Concept's ROIC of 174.86% is notably high, especially when compared to its WACC of 15.55%. This suggests that Venus Concept is efficiently using its capital to generate returns that far exceed its cost of capital. A high ROIC to WACC ratio of 11.25 further emphasizes the company's ability to create value for its investors, making it a potentially attractive investment.

In contrast, NeuroBo Pharmaceuticals has a negative ROIC of -574.82% and a WACC of 5.00%, resulting in a ROIC to WACC ratio of -114.95. This indicates that NeuroBo is not generating sufficient returns on its invested capital, which could be a concern for investors. Similarly, ThermoGenesis Holdings and Exicure also show negative ROICs, suggesting challenges in capital efficiency.

Plus Therapeutics stands out with a ROIC of 263.26% and a WACC of 6.09%, leading to a ROIC to WACC ratio of 43.26. This high ratio indicates that Plus Therapeutics is effectively generating returns on its invested capital, surpassing its cost of capital by a significant margin. This positions Plus Therapeutics as a strong contender in terms of capital efficiency and potential profitability.

Acutus Medical, with a ROIC of -0.24% and a WACC of 15.82%, has a ROIC to WACC ratio of -0.01. This suggests that Acutus Medical is struggling to generate returns that meet its cost of capital, which could impact its financial performance. Overall, while Venus Concept shows strong capital efficiency, Plus Therapeutics leads among its peers, indicating robust potential for growth and value creation.